PortfoliosLab logoPortfoliosLab logo
RSPH vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

RSPH vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RSPH achieves a -0.02% return, which is significantly lower than IDNA's 19.52% return.


RSPH

1D
1.18%
1M
2.30%
YTD
-0.02%
6M
-0.40%
1Y
12.03%
3Y*
3.36%
5Y*
2.44%
10Y*
8.68%

IDNA

1D
1.53%
1M
6.29%
YTD
19.52%
6M
16.84%
1Y
54.42%
3Y*
11.16%
5Y*
-8.18%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

RSPH vs. IDNA - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
-0.02%9.52%-0.94%3.95%-9.40%23.19%18.83%13.23%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
19.52%17.26%-0.72%-7.63%-42.28%-3.98%54.30%22.10%

Correlation

The correlation between RSPH and IDNA is 0.58, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.58

Correlation (3Y)
Calculated over the trailing 3-year period

0.61

Correlation (5Y)
Calculated over the trailing 5-year period

0.63

Correlation (All Time)
Calculated using the full available price history since Jun 13, 2019

0.63

The correlation between RSPH and IDNA has been stable across timeframes, ranging from 0.58 to 0.63 - a consistent structural relationship.

RSPH vs. IDNA - Sectors Allocation Comparison


Sectors
RSPH
IDNA

Healthcare

98.4%
99.3%

Financial Services

0.1%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

0.3%

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

RSPH
98.4%
IDNA
99.3%

Financial Services

RSPH
0.1%
IDNA

-

Basic Materials

RSPH

-

IDNA

-

Communication Services

RSPH

-

IDNA

-

Consumer Cyclical

RSPH

-

IDNA

-

Consumer Defensive

RSPH

-

IDNA

-

Energy

RSPH

-

IDNA

-

Industrials

RSPH

-

IDNA
0.3%

Real Estate

RSPH

-

IDNA

-

Technology

RSPH

-

IDNA

-

Utilities

RSPH

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RSPH vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RSPH
RSPH Risk / Return Rank: 2323
Overall Rank
RSPH Sharpe Ratio Rank: 2222
Sharpe Ratio Rank
RSPH Sortino Ratio Rank: 2222
Sortino Ratio Rank
RSPH Omega Ratio Rank: 2121
Omega Ratio Rank
RSPH Calmar Ratio Rank: 2424
Calmar Ratio Rank
RSPH Martin Ratio Rank: 2323
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 7474
Overall Rank
IDNA Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 7171
Sortino Ratio Rank
IDNA Omega Ratio Rank: 6060
Omega Ratio Rank
IDNA Calmar Ratio Rank: 8989
Calmar Ratio Rank
IDNA Martin Ratio Rank: 7878
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RSPH vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


RSPHIDNADifference
Sharpe ratioReturn per unit of total volatility

-1.43

Sortino ratioReturn per unit of downside risk

-1.84

Omega ratioGain probability vs. loss probability

1.14

1.34

-0.20

Calmar ratioReturn relative to maximum drawdown

1.11

5.13

-4.02

Martin ratioReturn relative to average drawdown

2.72

14.30

-11.58

RSPH vs. IDNA - Sharpe Ratio Comparison

The current RSPH Sharpe Ratio is 0.76, which is lower than the IDNA Sharpe Ratio of 2.19. The chart below compares the historical Sharpe Ratios of RSPH and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

RSPH vs. IDNA - Drawdown Comparison

The maximum RSPH drawdown since its inception was -40.49%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for RSPH and IDNA.


Loading charts...

Drawdown Indicators


RSPHIDNADifference

Max Drawdown

Largest peak-to-trough decline

-40.49%

-68.26%

+27.77%

Max Drawdown (1Y)

Largest decline over 1 year

-10.87%

-10.66%

-0.21%

Max Drawdown (3Y)

Largest decline over 3 years

-17.13%

-29.46%

+12.33%

Max Drawdown (5Y)

Largest decline over 5 years

-21.95%

-68.26%

+46.31%

Max Drawdown (10Y)

Largest decline over 10 years

-30.44%

Current Drawdown

Current decline from peak

-4.26%

-41.07%

+36.81%

Average Drawdown

Average peak-to-trough decline

-6.14%

-36.28%

+30.14%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.43%

3.82%

+0.61%

Volatility

RSPH vs. IDNA - Volatility Comparison

The current volatility for Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is 5.08%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 7.33%. This indicates that RSPH experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RSPHIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

5.08%

7.33%

-2.25%

Volatility (6M)

Calculated over the trailing 6-month period

10.86%

18.45%

-7.59%

Volatility (1Y)

Calculated over the trailing 1-year period

15.87%

24.96%

-9.09%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

16.34%

28.47%

-12.13%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

17.73%

29.51%

-11.78%

RSPH vs. IDNA - Expense Ratio Comparison

RSPH has a 0.40% expense ratio, which is lower than IDNA's 0.47% expense ratio.


Dividends

RSPH vs. IDNA - Dividend Comparison

RSPH's dividend yield for the trailing twelve months is around 0.73%, less than IDNA's 0.90% yield.


PositionTTM20252024202320222021202020192018201720162015
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
0.90%1.18%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%0.00%0.00%
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
0.73%0.70%0.71%0.66%0.64%0.50%0.51%0.54%0.53%0.47%0.48%0.49%

Frequently Asked Questions


RSPH and IDNA have a correlation of 0.58, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IDNA has higher volatility (7.33%) compared to RSPH (5.08%). In terms of maximum drawdown, RSPH dropped -40.49% vs IDNA's -68.26%.

On 5-year performance, RSPH leads with 2.44% vs -8.18% for IDNA. On fees, RSPH is cheaper at 0.40% per year. On volatility, RSPH has been the lower-risk option at 5.08%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, RSPH has performed better with a 2.44% return vs -8.18%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

RSPH is cheaper with a 0.40% expense ratio, compared with 0.47% for IDNA.

IDNA has the higher dividend yield at 0.90%, compared with 0.73% for RSPH.

RSPH tracks S&P 500 Equal Weighted / Health Care -SEC, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: Invesco and iShares. Their fees differ too: 0.40% for RSPH and 0.47% for IDNA.

IDNA currently has the higher Sharpe Ratio (2.19 vs 0.76), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RSPH and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer